Nicotinamide as a chemopreventive therapy of skin cancers. Too much of good thing ?

Abstract

The high incidence of keratinocyte cancers globally makes a chemopreventive approach to inhibit development of new skin cancers attractive. Chen and colleagues reported the results of a phase III double blind, randomized, placebo controlled clinical trial showing that nicotinamide (NAM), an amide form of vitamin B3, leads to a reduction in the rates of new keratinocyte cancers in patients who previously had skin cancer (Chen et al., 2015) (Figure 1).

This article is protected by copyright. All rights reserved.

from A via a.sfakia on Inoreader http://bit.ly/2Gzvg5Y